SCHEMBL3669967

SCHEMBL3669967

CC(=O)n1ncc2cc(-c3nnn(CC4CCOCC4)c3-c3ccc(F)cc3)ccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 4/20 0.62
DAPK3 O43293 2/20 0.38
MAPK14 Q16539 2/20 0.38
CLK4 Q9HAZ1 2/20 0.38
CHEK1 O14757 1/20 0.38
AURKA O14965 1/20 0.38
CSNK1A1 P48729 1/20 0.38
GSK3A P49840 1/20 0.38
LIMK1 P53667 1/20 0.38
IKBKE Q14164 1/20 0.38
TAOK1 Q7L7X3 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
RIPK3 Q9Y572 6/20 0.36
NR1H4 Q96RI1 1/20 0.35
GABRA5 P31644 2/20 0.35
DGAT1 O75907 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289776 0.86 CDC7 (0.57) CDC7DAPK3MAPK14CLK4CHEK1
SCHEMBL4289274 0.85 CDC7 (0.43) CDC7DAPK3MAPK14CLK4CHEK1
SCHEMBL3668081 0.77 CDC7 (1.00) CDC7DAPK3CLK4AURKAGSK3A
SCHEMBL4285256 0.73 CDC7 (0.57) CDC7DAPK3MAPK14CLK4CHEK1
SCHEMBL3672361 0.69 CDC7 (0.75) CDC7DAPK3MAPK14CLK4AURKA
SCHEMBL17373903 0.67 CHEK1 (0.67) DAPK3MAPK14CLK4CHEK1AURKA
SCHEMBL4289485 0.66 CLK4 (0.48) CDC7DAPK3MAPK14CLK4CHEK1
SCHEMBL4291536 0.66 CDC7 (0.54) CDC7DAPK3MAPK14CLK4CHEK1
SCHEMBL4295575 0.64 CDC7 (0.49) CDC7MAPK14RIPK3
SCHEMBL27788240 0.64 CDC7 (0.55) CDC7DAPK3CLK4AURKACSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885DAPK3 226/4885MAPK14 238/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885DAPK3 226/4885MAPK14 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.